Isis Pharmaceuticals Launches Trial, Hits Milestone

Biotech firm Isis Pharmaceuticals (NASDAQ: ISIS  ) announced in a press release recently  that it has begun a phase 2/3 clinical trial of its ISIS-TTR antisense drug for treating the rare genetic disease transthyretin (TTR) amyloidosis. The initiation of the trial also qualifies Isis for a $7.5 million milestone payment from its partner on the drug's development, GlaxoSmithKline (NYSE: GSK  ) .

TTR amyloidosis affects only around 50,000 individuals worldwide, according to Isis's statement. The disease causes progressive peripheral nerve and heart tissue dysfunction, with few treatments currently available for patients.

The FDA has already given orphan drug status and fast-track review designation for ISIS-TTR's treatment of familial amyloid neuropathy. The results from Isis's study will go toward supporting a regulatory application to market ISIS-TTR for treating this disease. Isis's international study will involve up to 200 patients for fifteen months, analyzing the effect of ISIS-TTR in patient neurological dysfunction and quality of life.

Isis's chief operating officer B. Lynne Parshall commented on the launch of the trial in the release, saying, "The encouraging data from our Phase 1 study, in which our drug was well tolerated and produced significant reductions in TTR protein, supported the advancement of ISIS-TTR(RX) directly into this registration-directed Phase 2/3."


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2270772, ~/Articles/ArticleHandler.aspx, 8/30/2014 10:37:43 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement